Evidence map›Paper›PMID 34983288›Full record

ArticleSmall GTPases2022

Deletion of murine

Hiroto Horiguchi, Haiming Xu, Beatrice Duvert, Felicia Ciuculescu, Qiuming Yao, Amit Sinha, Meaghan McGuinness, Chad Harris, Christian Brendel, Anja Troeger and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small GTPases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Hiroto HoriguchiDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Haiming XuDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Beatrice DuvertDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Felicia CiuculescuDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-9630-7055
Qiuming YaoDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Amit SinhaBasepairTech, New York, NY, USA.
Meaghan McGuinnessDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Chad HarrisDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Christian BrendelDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Anja TroegerDivision of Pediatric Hematology, Oncology and Hematopoietic Stem Cell Transplantation, University Hospital Regensburg, Regensburg, Bavaria, Germany.
Roberto ChiarleDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
David A WilliamsDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Boston Children's Hospital · USUniversity Hospital Regensburg · DE

Funding

Targeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI ASTER, JON C. · 2017 to 2021
$10.6M
Genetic Analysis and Manipulation Core (GAEC)P50HD105351 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI SCOTT Loren POMEROY, MUSTAFA SAHIN · 2021 to 2026
$9.4M
Mechanisms of resistance to ALK inhibitors in ALK-rearranged lymphomaR01CA196703 · NCI · BOSTON CHILDREN'S HOSPITAL · PI CHIARLE, ROBERTO · 2015 to 2025
$4.1M
RhoH GTPase in Hematopoiesis and CancerR01CA113969 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI WILLIAMS, DAVID A · 2005 to 2014
$3.0M
Development of novel selective Rac inhibitors for refractory leukemiasR01CA202756 · NCI · BOSTON CHILDREN'S HOSPITAL · PI WILLIAMS, DAVID A · 2016 to 2020
$3.0M
NCI NIH HHS P50 CA206963NCI NIH HHS R01 CA113969NCI NIH HHS R01 CA196703NCI NIH HHS R01 CA202756NICHD NIH HHS P50 HD105351
6 · The paper itself

Abstract

RHOH/TFF, a member of the RAS GTPase super family, has important functions in lymphopoiesis and proximal T cell receptor signalling and has been implicated in a variety of leukaemias and lymphomas. RHOH was initially identified as a translocation partner with BCL-6 in non-Hodgkin lymphoma (NHL), and aberrant somatic hypermutation (SHM) in the 5' untranslated region of the RHOH gene has also been detected in Diffuse Large B-Cell Lymphoma (DLBCL). Recent data suggest a correlation between RhoH expression and disease progression in Acute Myeloid Leukaemia (AML). However, the effects of RHOH mutations and translocations on RhoH expression and malignant transformation remain unknown. We found that aged Rhoh

Indexed as

LymphomaTranscription FactorsAnimalsCell Transformation, NeoplasticDisease Models, AnimalMiceMice, KnockoutMice, TransgenicPhenotypeProto-Oncogene Proteins c-bcl-6rho GTP-Binding ProteinsProto-Oncogene Proteins c-bcl-6rho GTP-Binding ProteinsRhoH protein, mouseTranscription FactorsZbtb33 protein, mouseB cellsBCL-6Blimp-1KAISOlymphomamalignant transformationRhoH

Identifiers

PMID34983288
PMCPMC8741284
OpenAlexW4206840290

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.